SEC Form SC 13G filed by Kazia Therapeutics Limited

11/6/24 7:53:45 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KZIA alert in real time by email

SC 13G 1 KaziaTherapeutics21.txt SC 13G Schedule 13G Name of issuer: Kazia Therapeutics Ltd Title of class of securities: Sponsored ADR Cusip: 48669G105 Date of event which requires filing: 09/30/2024 Rule 13d-1(b) 1. Platinum Investment Management Limited 2. (b) 3. 4. Sydney Australia 5. Platinum Investment Management Limited 0 (0%) Note:Combined total of underlying managed funds 6. N/A 7. Platinum Investment Management Limited 0 (0%) Note:Combined total of underlying managed funds 8. N/A 9. 0 10. No 11. 0% 12. IA Item 1. (a) Kazia Therapeutics Ltd (b) Three International Towers, Level 24, 300 Barangaroo Avenue, SYDNEY, NSW, Australia, 2000 Item 2. (a) Platinum Investment Management Limited (b) Level 8, 7 Macquarie Place Sydney NSW 2000 Australia (c) Australia (d) Sponsored ADR (e) 48669G105 Item 3. (e) An IA in accordance with Section 240.13d-1(b)(1)(ii)(e) Item 4. (a) 0 (b) 0% (c) (i) 0 (ii) 0 (iii) 0 (iv) 0 Item 5 Yes Item 6 The clients of Platinum Investment Management Ltd including pooled investment vehicles and other managed accounts have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Kazia Therapeutics Ltd. Item 7 N/A Item 8 N/A Item 9 N/A Item 10 (a) By signing below, I certify that to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. (b) N/A After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Get the next $KZIA alert in real time by email

Date	Price Target	Rating	Analyst
2/6/2025	$3.00	Buy	Maxim Group
10/14/2021	$18.00	Buy	Maxim Group

SEC Form SC 13G filed by Kazia Therapeutics Limited

Chat with this insight

Recent Analyst Ratings for
$KZIA

$KZIA
SEC Filings

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form SC 13G filed by Kazia Therapeutics Limited

Chat with this insight

Recent Analyst Ratings for $KZIA

$KZIA SEC Filings

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

SEC Form 424B3 filed by Kazia Therapeutics Limited

Recent Analyst Ratings for
$KZIA

$KZIA
SEC Filings